Business Profile of Symbiotec Pharmalab Limited
Symbiotec Pharmalab Ltd. was incorporated in 2002 and it is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients, nutritional ingredients, and specialty products. It supports pharmaceutical, nutraceutical, and wellness industries by delivering high-quality, innovative ingredients aligned with global standards. The company caters to domestic and international markets across regulated and emerging regions. As of June 30, 2025, they had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (“MT”) and fermentation capacity of 300 kilolitres.
Objective of Symbiotec Pharmalab Limited IPO
As per the draft red hearing prospects, the IPO issue consists fresh issue and offer for sale. The fresh issue consists of XXXX shares at the face value of ₨2.00 each aggregating up to ₹ 1,500.00 million and OFS consists XXXX shares at face value of ₨ 2.00 each aggregating up to Rs 20,300.00 million. There are fresh shares issues and OFS by company and main objective of company is re-payment of outstanding borrowings and general corporate purposes.
Details of Symbiotec Pharmalab Limited IPO
| IPO Open Date | N.A. |
| IPO Close Date | N.A. |
| Basis of Allotment | N.A. |
| Listing Date | N.A. |
| Face Value | ₹2.00 per share |
| Price | N.A. |
| Lot Size | N.A. |
| Total Issue Size | Up to XXXX Equity shares |
| Aggregating up to ₨ 21,800.00 million. | |
| Fresh Issue | Up to XXXX Equity Shares |
| Aggregating up to ₨ 1,500.00 million. | |
| Offer For Sale | Up to XXXX Equity Shares |
| Aggregating up to ₨ 20,300.00 million. | |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE & NSE |
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not more than 35% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
Symbiotec Pharmalab Limited IPO: Issue Price & Size
The issue price of SYMBIOTEC PHARMALAB LIMITED hasn’t been released yet. Upon releasing the dates, the investors can bid between those price ranges. The company has fresh issue and OFS aggregating up to ₹ 21,800.00 million at the price of ₨XXXX.
Launch Date of Symbiotec Pharmalab Limited IPO
The IPO opening date of SYMBIOTEC PHARMALAB LIMITED hasn’t been officially announced yet, upon the declaration of dates investor can bid for IPO.
Financial Statements of Symbiotec Pharmalab Limited
| Particulars (Rs in Millions) | Ended March 31 , 2025 |
Ended March 31 , 2024 |
Ended March 31 , 2023 |
| Income | |||
| Revenue from operations | 7,515.54 | 7,162.47 | 5,665.14 |
| Other income | 44.25 | 70.87 | 64.59 |
| Total income | 7,559.79 | 7,233.34 | 5,729.73 |
| Expenses | |||
| Cost of raw materials consumed | 2,854.88 | 3,126.30 | 3,084.16 |
| Change in inventories of finished goods and work in progress | 119.14 | 83.78 | ( 165.82 ) |
| Employee benefit expenses | 1,222.82 | 1,040.78 | 940.75 |
| Finance costs | 160.36 | 72.36 | 74.60 |
| Depreciation and amortization expense | 431.01 | 388.22 | 285.22 |
| Other expenses | 1,300.28 | 1,198.41 | 1,117.39 |
| Total expenses | 6,088.49 | 5,909.85 | 5,336.30 |
| Profit before tax and share of P&L of the JVs | 1,471.30 | 1,323.49 | 393.43 |
| Share of profit / ( loss ) of joint venture | ( 1.55 ) | ( 13.66 ) | ( 10.75 ) |
| Profit / ( Loss ) before tax | 1,469.75 | 1,309.83 | 382.68 |
| Tax expense | |||
| Income tax expense | 473.85 | 311.26 | 150.98 |
| Tax adjustments of earlier periods | 5.99 | ( 2.07 ) | 0.64 |
| Deferred Tax | 22.06 | 0.09 | ( 3.80 ) |
| Total Income tax expense | 501.90 | 309.28 | 147.82 |
| Profit ( Loss ) for the period | 967.85 | 1,000.55 | 234.86 |
Key financial ratios of Symbiotec Pharmalab Limited
| Particulars | Unit | Fiscal 2025 | Fiscal 2024 | Fiscal 2023 |
| Revenue from operations | INR million | 7,515.54 | 7,162.47 | 5,665.14 |
| EBITDA | INR million | 2,061.12 | 1,770.41 | 742.50 |
| EBITDA Margin | % | 27.26 % | 24.48 % | 12.96 % |
| Profit after Tax | INR million | 967.85 | 1,000.55 | 234.86 |
| PAT Margin ( % ) | % | 12.80 % | 13.83 % | 4.10 % |
| Net Debt | INR | 5,179.73 | 2,430.35 | 2,145.32 |
| Net debt / EBITDA | times | 2.51 | 1.37 | 2.89 |
| Net Worth | INR million | 8.211.52 | 7,206.76 | 6,211.70 |
| Return on equity ( % ) | % | 12.66 % | 14.98 % | NA |
| ROCE | % | 11.80 % | 14.03 % | 5.31 % |
| Gross fixed assets turnover ratio | times | 1.39 | 1.42 | NA |
| Net operating cash flow | INR million | 472.56 | 1,875.02 | 692.38 |
Promoters & Shareholding Symbiotec Pharmalab Limited IPO
As of date, according to the DRHP filed with SEBI promoters and promoter group have 35.07% shareholding in company.
| Name of Shareholder | No. of Equity Shares | % of total shareholding |
| Promoters & Promoter Group | 21,633,968 | 35.07 |
| Public | 40,047,528 | 64.93 |
| Total (A+B) | 61,681,496 | 100 |
Should You Subscribe To Symbiotec Pharmalab Limited IPO
While investing or subscribing to any IPO, consider the investment rationales related to the company. Hence, here you can find out the strength of the company that will be its growth factors. And also check the risk factors that can affect the growth and operational efficiency of the company.
Competitive Strengths of Symbiotec Pharmalab Limited IPO
Global leadership in specific APIs
The company has a global leadership position in corticosteroid and steroidal-hormone APIs in volume terms in Fiscal 2025, with a global volume market share of 36.2% in corticosteroid and 44.2% in steroidal-hormone APIs. It is supported by a comprehensive portfolio of over 60 corticosteroid and steroidal-hormone APIs, as of June 30, 2025, they spanning in both sterile and non-sterile formats.
Strong domestic & global client base
As of June 30, 2025, company served over 200 customers across more than 40 countries, supported by strong focus on quality assurance, scale of operations and ability to ensure consistent supply of complex APIs. The average relationship tenure is more than ten years with top five customers and more than nine years with top ten customers, underscoring its customer stickiness. Currently, company served over 200 customers across more than 40 countries, supported by its strong focus on quality assurance.
Well-positioned with strong R&D expertise
The innovation and an R&D-led development ethos have contributed to the growth of company operations and enabled to build capabilities in industrial-scale steroidal and hormonal organic chemistry, as well as fermentation technologies across modalities ranging from bioconversion to biosynthesis and precision fermentation. Through continuous investment in R&D, company have evolved from a lab-scale manufacturer enabling us to manufacture APIs and products collectively with up to 400 synthesis steps validated under cGMP efficiently.
High gross margins with robust cash conversion
The company has demonstrated a consistent track record of strong financial and operational performance. Their revenue from operations increased from ₹ 5,665.14 million in Fiscal 2023 to ₹ 7,162.47 million in Fiscal 2024 and further to ₹ 7,515.54 million in Fiscal 2025, representing a CAGR of 15.18% between Fiscals 2023 and 2025, and was ₹ 2,031.72 million in the three months period ended June 30, 2025, driven by robust global demand for our API products.
Risk Factors of Symbiotec Pharmalab Limited IPO
U.S. market exposure remains a concern
In the three months period ended June 30, 2025 and in Fiscals 2025, 2024 and 2023, revenue from the United States represented 11.61%, 4.02%, 8.97%, and 4.39% of our revenue from operations. The imposition of tariffs by the United States government under its “Fair and Reciprocal Plan” may impact Indian businesses, especially those with a substantial export presence in the United States market. This policy has resulted in the imposition of tariffs across a diverse range of sectors.
Client concentration risk
The company derives a substantial portion of revenue from certain key customers. Revenue generated from our top ten customers accounted for 64.01%, 55.90%, 61.65% and 60.65% of revenue from sale of product except one-off item in the three months period ended June 30, 2025 and in Fiscals 2025, 2024 and 2023, respectively. Loss of relationship with any of these customers or delays or reductions in their orders could have an adverse effect on business.
Raw material supply risks
The company procures a portion of its raw material requirements from different countries, including China and the United States. Any adverse developments in these countries, or the laws governing our imports from these countries, could disrupt raw material supply and adversely affect company results of operations, financial condition and cash flows.
Regulatory risk
The company is subject to extensive regulation from governmental and international authorities and if they fail to obtain, maintain or renew the statutory and regulatory licenses, permits and approvals required for business. Further, non-compliance with, and changes in, environmental, health and safety, and labor laws and other applicable regulations may adversely affect business, results of operations, financial condition and cash flows.
Symbiotec Pharmalab Limited IPO Grey Market Premium
Grey market premium is the premium quoted over the IPO issue price. GMP shows that investors are ready to pay above the upper band of the IPO issue price. GMP is determined in the grey market as per the demand and supply of the shares in the primary market. A grey market is that unofficial ecosystem of unlisted companies’ stocks that start trading even before the launch of the IPO to the date of its listing.
Also Read: What is Grey Market Premium in IPO: How is GMP Calculated & Reliable
However, GMP is not a reliable factor, as it keeps fluctuating as per the demand and supply of shares in the primary market. There are numerous factors that affect the stock market in India and individual stock prices of different companies that are already listed and trading in the secondary market. However, for an IPO-bounded company, you can consider the GMP as the speculative listing price of the share
According to various online sources, the Grey Market Premium or GMP of the SYMBIOTEC PHARMALAB LIMITED is trading around Rs XX in the grey market. It means shares are trading at the upper band issue price of Rs XX with a premium in the grey market and may list around the same price.
